- Angelini to buy Catalyst in $4B play for rare neuro drugs<figure><div><img src="https://imgproxy.divecdn.com/4_eQ3BQP0sHe3AjR5s7bySznoaDhyqMpmhkmNubOdkU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDQwMTY4MDMyXzEua…BioPharma Dive · 2mo ago↗ source
- Entrada shares dive as Duchenne results disappoint<figure><div><img src="https://imgproxy.divecdn.com/xa_T0oT9Hj8F-wJjKfJeFkbn4Yqp_lT58dL0S4GszxY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02MjEzNjQ4MDJfMS5qc…BioPharma Dive · 2mo ago↗ source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...